Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells.

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Cancer Research

• Publication date

  2003-05-01

• Fields of study

  Medicine

• Identifiers
  PMID 12727829
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Extracellular mRNA Induces Dendritic Cell Activation by Stimulating Tumor Necrosis Factor-α Secretion and Signaling through a Nucleotide Receptor*

  2002cited by this paper
• Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors.

  2002cited by this paper
• Rapid Induction of Tumor-specific Type 1 T Helper Cells in Metastatic Melanoma Patients by Vaccination with Mature, Cryopreserved, Peptide-loaded Monocyte-derived Dendritic Cells

  2002cited by this paper
• Enhanced induction of telomerase-specific CD4(+) T cells using dendritic cells transfected with RNA encoding a chimeric gene product.

  2002cited by this paper
• Histone deacetylase inhibitors suppress telomerase reverse transcriptase mrna expression in prostate cancer cells

  2002cited by this paper
• Dendritic Cell-Based Xenoantigen Vaccination for Prostate Cancer Immunotherapy1

  2001cited by this paper
• Expression and immunogenicity of oncofetal antigen-immature laminin receptor in human renal cell carcinoma.

  2001cited by this paper
• Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine.

  2001cited by this paper
• Induction of Polyclonal Prostate Cancer-Specific CTL Using Dendritic Cells Transfected with Amplified Tumor RNA1

  2001cited by this paper
• WT1 proteins: functions in growth and differentiation.

  2001cited by this paper
• Dendritic cells in cancer immunotherapy.

  2000cited by this paper
• HIV Gag mRNA Transfection of Dendritic Cells (DC) Delivers Encoded Antigen to MHC Class I and II Molecules, Causes DC Maturation, and Induces a Potent Human In Vitro Primary Immune Response1

  2000cited by this paper
• Human Dendritic Cells Transfected with RNA Encoding Prostate-Specific Antigen Stimulate Prostate-Specific CTL Responses In Vitro1

  2000cited by this paper
• The detection of renal carcinoma cells in the peripheral blood with an enhanced reverse transcriptase–polymerase chain reaction assay for MN/CA9

  1999cited by this paper
• A New Antigen Recognized by Cytolytic T Lymphocytes on a Human Kidney Tumor Results from Reverse Strand Transcription

  1999cited by this paper
• Cellular and humoral immune responses in patients with metastatic renal cell carcinoma after vaccination with antigen pulsed dendritic cells.

  1999cited by this paper
• Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma. Canadian Urologic Oncology Group.

  1998cited by this paper
• Cancer statistics, 1998

  1998cited by this paper
• Fully mobilizing host defense: Building better vaccines

  1998cited by this paper
• The Antigen t Cell Receptor: Selected Protocols and Applications

  1997cited by this paper
• Nephrectomy before interleukin-2 therapy for patients with metastatic renal cell carcinoma.

  1997cited by this paper
• Immunoselection in vivo: Independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma

  1997cited by this paper
• Cloning and characterization of MN, a human tumor-associated protein with a domain homologous to carbonic anhydrase and a putative helix-loop-helix DNA binding segment.

  1994cited by this paper
• Cancer statistics

  1989cited by this paper

• Comparative efficacy, immune response, and safety of mRNA versus dendritic cell vaccines in solid tumors: a systematic review and meta-analysis

  2026cites this paper
• Immunogenicity of neoantigens: From CAR-T cell to various vaccines.

  2025cites this paper
• The opportunities and barriers for developing tumour-infiltrating lymphocyte therapy for patients with advanced genitourinary cancers.

  2025cites this paper
• The Role of Therapeutic Vaccines in Cancer Immunotherapy

  2025cites this paper
• Advances of mRNA vaccines in genitourinary cancers.

  2025cites this paper
• Cancer vaccines: an update on recent achievements and prospects for cancer therapy

  2024cites this paper
• Targeting Telomere Dynamics as an Effective Approach for the Development of Cancer Therapeutics

  2024cites this paper
• Overview on Immunopathology of Chronic Lymphocytic Leukemia and Tumor-Associated Antigens with Therapeutic Applications

  2024cites this paper
• Cancer mRNA vaccines: clinical advances and future opportunities

  2024cites this paper
• Clinical benefit and safety associated with mRNA vaccines for advanced solid tumors: A meta‐analysis

  2023cites this paper
• RNA modification in mRNA cancer vaccines

  2023cites this paper
• Dendritic Cell Vaccines: A Shift from Conventional Approach to New Generations

  2023cites this paper
• Biological and clinical perspectives of TERT promoter mutation detection on bladder cancer diagnosis and management.

  2022cites this paper
• The Quest for mRNA Vaccines

  2022cites this paper
• Application of mRNA Technology in Cancer Therapeutics

  2022cites this paper
• Immunopharmacogenomics: a hope in the treatment of carcinoma

  2022cites this paper
• The current clinical landscape of personalized cancer vaccines.

  2022cites this paper
• Vaccination with Messenger RNA: A Promising Alternative to DNA Vaccination.

  2021cites this paper
• Biological Therapies in the Treatment of Cancer—Update and New Directions

  2021cites this paper
• DNA Vaccines: Methods and Protocols

  2021cites this paper
• Cancer Immunoprevention: Current Status and Future Directions

  2021cites this paper
• An Overview on the Development of mRNA-Based Vaccines and Their Formulation Strategies for Improved Antigen Expression In Vivo

  2021influential citation
• Current status of antigen-specific T-cell immunotherapy for advanced renal-cell carcinoma

  2021cites this paper
• mRNA therapeutics in cancer immunotherapy

  2021cites this paper
• Targeting Neuroinflammation in Brain Cancer: Uncovering Mechanisms, Pharmacological Targets, and Neuropharmaceutical Developments

  2021cites this paper
• Electroporation as a method of choice to generate genetically modified dendritic cell cancer vaccines.

  2020cites this paper
• Therapeutic Cancer Vaccination with Ex Vivo RNA-Transfected Dendritic Cells—An Update

  2020influential citation
• Antitumour dendritic cell vaccination in a priming and boosting approach

  2020cites this paper
• Novel immunotherapy combinations for genitourinary cancers

  2020cites this paper
• Neoantigen-based immunotherapy in pancreatic ductal adenocarcinoma (PDAC).

  2020cites this paper
• Ribonucleic Acid Engineering of Dendritic Cells for Therapeutic Vaccination: Ready ‘N Able to Improve Clinical Outcome?

  2020cites this paper
• Adjuvant-pulsed mRNA vaccine nanoparticle for immunoprophylactic and therapeutic tumor suppression in mice

  2020cites this paper
• Breakthrough concepts in immune‐oncology: Cancer vaccines at the bedside

  2020cites this paper
• Immunotherapy with mRNA vaccination and immunomodulation nanomedicine for cancer therapy

  2019cites this paper
• Genetic Vaccine for Cancer

  2019cites this paper
• Sorghumol triterpene inhibits the growth of circulating renal cancer cells by promoting cell apoptosis, G2/M cell cycle arrest and downregulating m-TOR/PI3K/AKT signalling pathway.

  2019cites this paper
• RNA-loaded dendritic cells: more than a tour de force in cancer therapeutics.

  2019cites this paper
• A 3D Macroporous Alginate Graphene Scaffold with an Extremely Slow Release of a Loaded Cargo for In Situ Long‐Term Activation of Dendritic Cells

  2019cites this paper
• NPM-ALK-reactive T-cell responses in children and adolescents with NPM-ALK positive anaplastic large cell lymphoma

  2019cites this paper
• Tumor Antigens

  2019cites this paper
• Preliminary report of a novel formulation of clinical-grade, fully matured, tumor-associated peptide-loaded dendritic cells for cancer immunotherapy

  2019cites this paper
• Strategies for developing and optimizing cancer vaccines

  2019cites this paper
• Induction of T cell‐mediated immune response by dendritic cells pulsed with mRNA of sphere‐forming cells isolated from patients with gastric cancer

  2019cites this paper
• Immune Cell Vaccine for Cancer

  2019cites this paper
• Automated Good Manufacturing Practice-compliant generation of human monocyte-derived dendritic cells from a complete apheresis product using a hollow-fiber bioreactor system overcomes a major hurdle in the manufacture of dendritic cells for cancer vaccines.

  2019cites this paper
• DESIGNING A VACCINE FOR CANCER: A LOOK INTO DENDRITIC CELL CANCER VACCINE

  2019cites this paper
• Immune Check Point CD40–CD40L Activates Dendritic and Effector Cells Against Human Renal Carcinoma Cells

  2019cites this paper
• Dendritic cells as cancer therapeutics.

  2019cites this paper
• Correction of bleeding in experimental severe hemophilia A by systemic delivery of factor VIII-encoding mRNA

  2019cites this paper
• Immunological Cellular Therapies and Gene Therapies

  2018cites this paper
• Dendritic Cell Vaccines Presenting Autologous Tumor Antigens from Self-renewing Cancer Cells in Metastatic Renal Cell Carcinoma

  2018cites this paper
• A randomized phase II clinical trial of dendritic cell vaccination following complete resection of colon cancer liver metastasis

  2018influential citation
• In vivo cancer vaccination: Which dendritic cells to target and how?

  2018cites this paper
• Automated closed-system manufacturing of human monocyte-derived dendritic cells for cancer immunotherapy.

  2018cites this paper
• Latest development on RNA-based drugs and vaccines

  2018cites this paper
• The Role of the Nucleosome Remodeling Factor NURF in Inhibiting T and Natural Killer Cell Mediated Antitumor Immunity by Suppressing Tumor Antigenicity and Natural Cytotoxicity Receptor Co-ligands

  2017cites this paper
• Recent Advances in the Function of the 67 kDa Laminin Receptor and its Targeting for Personalized Therapy in Cancer.

  2017cites this paper
• Enhanced cytotoxic activity of effector T-cells against cholangiocarcinoma by dendritic cells pulsed with pooled mRNA

  2017cites this paper
• Dendritic‐cell‐based immunotherapy evokes potent anti‐tumor immune responses in CD105+ human renal cancer stem cells

  2017cites this paper
• A second chance for telomerase reverse transcriptase in anticancer immunotherapy

  2017cites this paper
• A generic RNA pulsed DC based approach for developing therapeutic intervention against nasopharyngeal carcinoma

  2017cites this paper
• Recent advances in immuno‐oncology and its application to urological cancers

  2016cites this paper
• Dendritic Cell Vaccines.

  2016cites this paper
• Past, present and forecast of transfusion medicine: What has changed and what is expected to change?

  2016cites this paper
• Biomanufacturing of Therapeutic Cells: State of the Art, Current Challenges, and Future Perspectives.

  2016cites this paper
• Gene-modified dendritic cell vaccines for cancer.

  2016cites this paper
• Generation of Large Numbers of Antigen-Expressing Human Dendritic Cells Using CD14-ML Technology

  2016cites this paper
• Immune response and long-term clinical outcome in advanced melanoma patients vaccinated with tumor-mRNA-transfected dendritic cells

  2016cites this paper
• mRNA Cancer Vaccines.

  2016cites this paper
• Therapeutic Targeting of Telomerase

  2016cites this paper
• Personalized approaches to active immunotherapy in cancer.

  2016cites this paper
• Tumor antigen-specific T cells for immune monitoring of dendritic cell-treated glioblastoma patients.

  2016cites this paper
• mRNA-based therapeutics–Advances and perspectives

  2016cites this paper
• RNA-Based Vaccines in Cancer Immunotherapy

  2015cites this paper
• Insights on Peptide Vaccines in Cancer Immunotherapy

  2015cites this paper
• Immunotherapy in Metastatic Renal Cell Carcinoma: A Comprehensive Review

  2015cites this paper
• Vaccines in RCC: Clinical and Biological Relevance

  2015cites this paper
• Prophylactic Dendritic Cell-Based Vaccines Efficiently Inhibit Metastases in Murine Metastatic Melanoma

  2015cites this paper
• Recombinant messenger RNA technology and its application in cancer immunotherapy, transcript replacement therapies, pluripotent stem cell induction, and beyond

  2015cites this paper
• Immunogenicity of GX301 cancer vaccine: Four (telomerase peptides) are better than one

  2015cites this paper
• Whole Tumor Antigen Vaccines: Where Are We?

  2015cites this paper
• Recently, the first autologous DC-based therapy was approved by the Food and Drug Administration (FDA) for treatment of patients with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC). Sipuleucel-T (known by the trade name, “Provenge”) is a cellular vaccin

  2015cites this paper
• Long-term survival correlates with immunological responses in renal cell carcinoma patients treated with mRNA-based immunotherapy

  2015cites this paper
• Acquisition and Presentation of Tumor Antigens by Dendritic Cells.

  2015cites this paper
• mRNA-based dendritic cell vaccines

  2015cites this paper
• Dendritic Cell Vaccination

  2014cites this paper
• Current Tactics Employed in Cancer Vaccines and Their Progress

  2014cites this paper
• Immunotherapy in Renal Cell Carcinoma

  2014cites this paper
• Genetically Modified Dendritic Cell Vaccines for Solid Tumors

  2014cites this paper
• Clinical use of dendritic cells for cancer therapy.

  2014cites this paper
• Recognition and Killing of Autologous, Primary Glioblastoma Tumor Cells by Human Cytomegalovirus pp65-Specific Cytotoxic T Cells

  2014cites this paper
• Making sense of dietary calcium and urinary stone disease

  2014cites this paper
• Cancer Therapy : Preclinical Recognition and Killing of Autologous , Primary Glioblastoma Tumor Cells by Human Cytomegalovirus pp 65-Speci fi c Cytotoxic T Cells

  2014cites this paper
• RNAVaccines in Cancer Treatment

  2014cites this paper
• Enriquecimento antigênico de linhagens tumorais: estratégia para abordagens imunoterapêuticas personalizadas

  2014cites this paper
• Dendritic cells transfected with hepatocellular carcinoma (HCC) total RNA induce specific immune responses against HCC in vitro and in vivo

  2014cites this paper
• Priming of cytotoxic T lymphocyte responses by dendritic cells: induction of potent anti-tumor immune responses

  2013cites this paper
• Molecular Immunotherapeutics and Vaccines for Renal Cell Carcinoma and Its Vasculature

  2013cites this paper
• Induction of Cell Death in Renal Cell Carcinoma With Combination of D-Fraction and Vitamin C

  2013cites this paper
• Novel perspectives on dendritic cell-based immunotherapy of cancer.

  2013cites this paper